Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | DDO | Q99489 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662168 | 0.90 | ROCK2 (0.34) | HCAR1TNKSTNKS2 | |
| SCHEMBL7654621 | 0.86 | HCAR1 (0.43) | HCAR1PARP1PTGER3 | |
| SCHEMBL7238892 | 0.86 | HCAR1 (0.40) | HCAR1 | |
| SCHEMBL2658794 | 0.83 | HCAR1 (0.36) | HCAR1PARP1DAODDO | |
| SCHEMBL2657831 | 0.80 | MEN1 (0.45) | PARP1MEN1HSP90AA1KMT2A | |
| SCHEMBL7238741 | 0.80 | HCAR1 (0.34) | HCAR1PARP1TNKSTNKS2 | |
| SCHEMBL7241224 | 0.75 | HCAR1 (0.48) | HCAR1 | |
| SCHEMBL7240781 | 0.71 | HCAR1 (0.47) | HCAR1MEN1HSP90AA1KMT2A | |
| SCHEMBL22016868 | 0.63 | ATAD2 (0.64) | PARP1DAOPDE3BPDE3A | |
| SCHEMBL1878872 | 0.63 | HCAR1 (0.39) | HCAR1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073717-A1 | Triazolo-pyridine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-04-17 | — | — | US | disclosed |
| US-6479506-B1 | USEFUL IN THE THERAPY OF DELETERIOUS MENTAL STATES SUCH AS ANXIETY | MERCK SHARP & DOHME LTD. (GB) | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073717-A1 | Triazolo-pyridine derivatives as ligands for GABA receptors | GABRA3, GABRA4, GABRA5 | HCAR1 240/4885PARP1 2497/4885TNKS 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.